Published • loading... • Updated
Novartis Q3 Profit Declines; Lifts FY26 Core Income View, Backs Sales Outlook
Novartis said core earnings rose 11% and sales increased 4% as priority brands offset generic erosion.
- On Tuesday, Novartis AG reported a 70% third-quarter profit decline to $1.196 billion, primarily due to a $1.9 billion partial impairment charge of the del-desiran asset.
- Despite the impairment, Novartis reported net sales grew 4% to $14.522 billion, driven by priority brands including Kisqali, Kesimpta, Scemblix, Leqvio, and Cosentyx.
- Earnings per share fell to 63 cents from $2.04 a year ago, though core earnings of $2.46 exceeded the $2.25 estimate from Zacks Investment Research.
- CEO Vas Narasimhan said the company is "well on track to deliver our mid- and long-term outlook," citing productivity efforts and sales growth.
- Novartis raised its fiscal 2026 outlook for core operating income to low single-digit growth while confirming annual net sales expectations.
Insights by Ground AI
21 Articles
21 Articles
Novartis raised its projections of results for the year, citing a solid growth in sales and productivity gains, even with recent setbacks in clinical trials that impacted the profit of Swiss pharmacists in the third quarter. Exclusive material for subscribers. To have full access, access the link of the subject and register.
·Rio de Janeiro, Brazil
Read Full Article
Coverage Details
Total News Sources21
Leaning Left0Leaning Right1Center9Last UpdatedBias Distribution90% Center
Bias Distribution
- 90% of the sources are Center
90% Center
C 90%
Factuality
To view factuality data please Upgrade to Premium
